AbbVie to take over Cerevel Therapeutics in $8.7B deal



AbbVie Inc. revealed in a statement it will be acquiring Cerevel Therapeutics Hldg in an agreement valued at $8.7 billion or $45 per share.

The deal is expected to boost AbbVie’s neuroscience por…

About the author:

Get involved!

Fai trading in gruppo!
L'unica Academy di trading completamente gratuita per gli utenti FpMarkets

Comments

Ancora nessun commento